Karen Nash
Karen Nash is a medical reporter and media consultant based in Monroeville, PA.
U.S. Preventive Services Task Force report on PSA is another reason for men to avoid the doctor, urologists say
Most urologists say they've already seen reaction to the report's release and the resulting news coverage. Many are concerned that the USPSTF recommendation will give men another excuse to avoid the doctor's office.
Urologists often on the 'defensive' when ordering tests
Urology Times asks five urologists about diagnostic tests and practicing 'defensive' medicine.
Are you using (or will you use) onabotulinumtoxinA to treat certain patients with urinary incontinence?
Urology Times asked urologists if they would use botulinum toxin to treat urinary incontinence.
Planning to merge a urology practice? Tips for a smooth transition
As has happened throughout the field of medicine over the past decade, a growing number of urologists are merging to create larger, more expansive urology practices. Here's how one newly merged practice stayed on track during the merger process.
Urology practice change coming in the form of new alliances, accountable care organizations
Many urologists are embarking on practice-changing moves, including forming new alliances with area hospitals or other practices and gearing up for participation in accountable care organizations (ACOs).
What's the one piece of equipment you can't live without as a urologist?
Three urologists share their favorite instrument used in their practices.
Urologists say poor efficacy, cost, side effects drive drug noncompliance
Not all patients follow their urologist's recommendations, and Urology Times asked urologists around the country to share their experience with—and advice about—patient noncompliance.
Are you seeing more renal stones in your younger patients?
Urologists' reports of stones in pediatric patients varies by region.
Active surveillance for prostate cancer an imperfect science, urologists say
Urologists share when they offered surveillance, what protocol they used, and how patients responded to this alternative to immediate treatment for low-risk prostate cancer.

Poll